Can a simple pill help liver cancer patients eat better?

NCT ID NCT07565415

Not yet recruiting Symptom relief Sponsor: Nanfang Hospital, Southern Medical University Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 2 trial tests whether a drug called nanocrystalline megestrol acetate can help people with advanced liver cancer who are losing weight and appetite. About 88 patients will receive either the drug or a placebo for 12 weeks while also getting standard cancer therapy. The goal is to see if the drug prevents weight loss and improves quality of life.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: nanocrystalline megestrol acetate (a hormone-like drug to boost appetite)
What this could lead to: If it works, this could provide a way to help liver cancer patients maintain weight and appetite during treatment, improving quality of life.
What could go wrong: This is an early Phase 2 trial with only 88 participants, so results may not apply to everyone. The drug may cause side effects like fluid retention or blood clots.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANOREXIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Anorexia anorexia nervosa Cachexia hepatocellular carcinoma Malnutrition nutritional deficiency disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANOREXIA CACHEXIA HEPATOCELLULAR CARCINOMA (HCC) MALNUTRITION

Contacts and locations

Locations

Nanfang Hospital of Southern Medical University

Guangzhou, Guangdong, 510515, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.